Frontiers in Cardiovascular Medicine · Nov 16, 2026
Trends in Population Mortality Involving Dilated Cardiomyopathy and Heart Failure in the United States From 1999 to 2024: A CDC WONDER Database Study
By Xiongda Yao, Ren-Qiang Yang, Yue Zhou et al.
Background: Long-term population mortality patterns involving co-recorded dilated cardiomyopathy (DCM) and heart failure (HF) remain insufficiently characterized. We examined temporal trends and disparities in DCM-and HF-related mortality in the United States from 1999 to 2024. Methods: Mortality data for US residents aged ≥25 years were obtained from the CDC WONDER Multiple Cause of Death datasets. Deaths involving DCM (ICD-10: I42.0) and HF-related conditions (I11.0, I13.0, I13.2, or I50) were identified. Age-adjusted mortality rates (AAMRs) were assessed by sex, race and ethnicity, and geographic characteristics; age-specific mortality rates were used for age-stratified analyses. Joinpoint regression estimated annual percentage changes (APCs) and average annual percentage changes (AAPCs). Results: During 1999–2024, 50,300 deaths were identified. National AAMR declined overall during 1999–2024, with an AAPC of −2.72% (95% CI, −3.19 to −2.22). The estimated increase during 2014 – 2022 was not statistically significant; the long-term decline persisted when DCM was required as the underlying cause. The steepest decline occurred during 2005–2014 (APC, −7.40%). AAMRs were higher among men and non-Hispanic Black individuals. Age-specific rates were highest at older ages. The three older groups had negative full-period AAPCs, but later APCs were positive: 2.10% for ages 65–74 during 2013–2024, and 2.85% and 4.01% for ages 75–84 and ≥85, respectively, during 2015–2024. Conclusions: The national long-term decline coexisted with later increases within older age groups, warranting continued attention to mortality in aging populations. Continued population surveillance, particularly in older age groups, is warranted.